Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 738 citations

Medicine, Oncology, Pharmacology +17

Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity

Hwei‐Ru Tsou, Elsebe G. Overbeek-Klumpers, William Hallett et al. · Journal of Medicinal Chemistry · 2005 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

Allan Wissner, Elsebe Overbeek, Marvin F. Reich et al. · Journal of Medicinal Chemistry · 2002 · 266 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Mechanism of the Stille Reaction. 1. The Transmetalation Step. Coupling of R¹I and R²SnBu₃ Catalyzed by <i>trans</i>-[PdR¹IL₂] (R¹ = C₆Cl₂F₃; R² = Vinyl, 4-Methoxyphenyl; L = AsPh₃)

Arturo L. Casado, Pablo Espinet · Journal of the American Chemical Society · 1998 · 223 citations

Natural Sciences, Chemistry, Catalysis +13

Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors:  4-(Phenylamino)pyrazolo[3,4-<i>d</i>]pyrimidines

Peter Traxler, Guido Bold, Joerg Frei et al. · Journal of Medicinal Chemistry · 1997 · 205 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17